Evaluating the efficacy of the endoscopic thyroidectomy via sternocleidomastoid muscle posteroinferior approach in identifying occult lateral cervical lymph node metastasis
Original Article

Evaluating the efficacy of the endoscopic thyroidectomy via sternocleidomastoid muscle posteroinferior approach in identifying occult lateral cervical lymph node metastasis

Yixin Jing ORCID logo, Jing Zhou, Xinmeng Qi, Jun Wu, Hongfei Liu, Junwei Huang, Xiao Chen, Lifeng Li, Zhigang Huang, Yiming Ding, Xiaohong Chen ORCID logo

Department of Thyroid Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China

Contributions: (I) Conception and design: Y Jing; (II) Administrative support: Y Ding, Xiaohong Chen; (III) Provision of study materials or patients: J Zhou, X Qi, J Wu; (IV) Collection and assembly of data: Y Jing, J Wu, H Liu; (V) Data analysis and interpretation: Y Jing; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Xiaohong Chen, MD; Yiming Ding, MD. Department of Thyroid Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, No. 1 Dongjiaominxiang Street, Dongcheng District, Beijing 100005, China. Email: trchxh@163.com; dyment@126.com.

Background: Lateral cervical lymph node metastasis (LLNM) is a well-established prognostic factor influencing recurrence and survival in patients with papillary thyroid carcinoma (PTC). However, the accuracy of preoperative imaging examinations is limited. We have pioneered a minimally invasive technique—endoscopic thyroidectomy via sternocleidomastoid muscle posteroinferior approach (ETSPIA). This technique facilitates selective lateral neck lymph node dissection while excising thyroid lesions, effectively eradicating occult lateral cervical lymph node metastasis (OLLNM) without the need for extended incisions. This study investigates the diagnostic and therapeutic value of ETSPIA in managing OLLNM in PTC.

Methods: A retrospective analysis was conducted on the clinical data of 142 patients with primary PTC who underwent ETSPIA at Beijing Tongren Hospital from November 2022 to June 2024. All patients underwent lateral cervical lymph node exploration: intraoperative examination first targeted the medial lymph nodes of the internal jugular vein, with frozen section analysis; if positive, the external lymph nodes of the internal jugular vein were subsequently addressed. The study recorded cases of LLNM and analyzed factors influencing OLLNM.

Results: Excluding 8 patients with preoperatively detected evident LLNM via ultrasound, 33 out of 134 patients (24.6%) exhibited OLLNM. This subgroup included 19 males and 14 females, with a median age of 34 years. The tumor-node-metastasis (TNM) staging revealed 17 cases of T1a, 7 cases of T1b, 4 cases of T2, and 4 cases of T3b. The tumors were located in the thyroid upper pole in 12 cases, the middle part in 15 cases, and the lower pole in 6 cases, with 26 cases presenting with solitary tumors and 7 with multiple lesions. Extrathyroidal extension was observed in 4 cases. Over a median follow-up period of 17 months, no severe complications were reported. Univariate analysis identified male gender, younger age, tumor T stage, preoperative ultrasound indication of upper pole thyroid tumors, and extrathyroidal extension as factors associated with OLLNM (P<0.001, P=0.02, P=0.007, P<0.001, P=0.003 respectively). Multivariate regression analysis demonstrated that male gender, younger age, and preoperative ultrasound indication of upper pole thyroid tumors were independent risk factors for OLLNM in PTC (P=0.001, P=0.006, P=0.02, P=0.002, respectively).

Conclusions: As a novel minimally invasive endoscopic thyroid approach, ETSPIA allows for the excision of thyroid lesions while addressing lateral cervical metastatic lymph nodes. It demonstrates favorable cosmetic outcomes and safety, offering a viable alternative for the management of thyroid cancer.

Keywords: Radical resection of thyroid cancer; occult lateral cervical lymph node metastasis (OLLNM); sternocleidomastoid muscle posteroinferior approach; minimally invasive


Submitted Aug 09, 2024. Accepted for publication Nov 07, 2024. Published online Nov 26, 2024.

doi: 10.21037/gs-24-340


IntroductionOther Section

Thyroid cancer ranks ninth in global cancer incidence and has emerged as the fastest-growing malignant tumor in recent years. By 2030, it is expected to become the second most common malignant tumor among females, with an increasingly younger age of onset (1). Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer and has a relatively low mortality and good prognosis compared to other common malignancies. However, PTC is prone to lymph node metastasis, and studies have shown that patients evaluated preoperatively for clinical negative lymph node (cN0), the incidence of central cervical lymph node metastasis (CLNM) ranges from 30% to 80% (2), and lateral cervical lymph node metastasis (LLNM) ranges from 18% to 64% (3-5). Patients with LLNM exhibit higher rates of postoperative recurrence and distant metastasis (6).

Preoperative ultrasound and neck enhanced computer tomography (CT) are commonly used to screen for cervical lymph node metastasis, yet their sensitivity (23–67%), specificity (70–79%), and accuracy (70–91%) are limited (7,8). Therefore, a considerable number of cervical lymph node metastasis of PTC cannot be detected before operation. Current guidelines do not recommend prophylactic cervical dissection for PTC patients with a preoperative cN0 assessment (9), resulting in residual cervical lymph node metastasis and increased risk of postoperative recurrence and secondary surgery. Occult lateral cervical lymph node metastasis (OLLNM) refers to negative clinical evaluation and imaging examination (B-ultrasound, CT, magnetic resonance imaging, etc.), but positive intraoperative or postoperative pathological examination of the lateral cervical lymph node (10). This condition is often overlooked by surgeons. Traditional anterior cervical median approach thyroid surgery for lymph node dissection results in a longer incision and prominent postoperative scarring, conflicting with aesthetic considerations. Conventional endoscopic thyroid surgeries, such as oral, axillary, and subclavian approaches, pose difficulties in cervical lymph node dissection.

Our team has developed a novel minimally invasive technique: endoscopic thyroidectomy via sternocleidomastoid muscle posteroinferior approach (ETSPIA). This approach facilitates the removal of latent cervical lymph node metastasis without extending the incision. In this study, we retrospectively analyzed 142 PTC patients who underwent ETSPIA to evaluate its efficacy in clearing OLLNM without increasing patient incision or trauma. Additionally, we investigated the risk factors associated with PTC OLLNM. We present this article in accordance with the TREND reporting checklist (available at https://gs.amegroups.com/article/view/10.21037/gs-24-340/rc).


MethodsOther Section

Patients

A retrospective study was performed on 142 patients diagnosed with PTC who underwent ETSPIA at the Thyroid Head and Neck Surgery Department of Beijing Tongren Hospital, Capital Medical University from November 2022 to June 2024. The patient cohort comprised 43 males and 99 females, aged 22 to 60 years, with a median age of 43 years. All participants were in generally good health, free of significant underlying conditions, and had thyroid nodules detected during routine physical examinations. Preoperative ultrasound assessments of the thyroid and cervical lymph nodes were conducted in our hospital.

Inclusion criteria for the study encompassed: (I) undergoing thyroid surgery for the first time; (II) primary thyroid lesion confirmed as PTC through pathological examination; (III) preoperative imaging indicating a maximum thyroid nodule diameter of ≤4 cm and a maximum lymph nodes diameter of <2 cm. Exclusion criteria were: (I) preoperative thyroid dysfunction or thyroid endocrine disorders; (II) previous history of cervical surgery, radiotherapy, or thermal ablation; and (III) presence of other systemic malignancies. Criteria for PTC cervical lymph node ultrasound included exclusion of secondary lesions, unclear or absent hilar-pulp structure, presence of central microcalcifications, peripheral or mixed blood flow patterns, and cystic changes in lymph nodes.

Comprehensive data on clinical features, pathological findings, and perioperative outcomes were systematically recorded. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This retrospective study was approved by the Beijing Tongren Hospital Ethics Committee (No. TREC2023-xjs07) and informed consent was taken from all of the patients.

Operative procedure

All patients were operated on by the same head and neck surgeon with extensive clinical experience. (I) Body position and incision design. The patient is positioned supine with the head in a neutral midline orientation. A lateral neck incision is made following the natural skin crease, located 1 cm posterior to the sternocleidomastoid muscle, extending from anterior to posterior with a length of 3.5 to 4.5 cm. The transverse cervical nerve, great auricular nerve, accessory nerve, lesser occipital nerve, and external jugular vein are carefully dissected and preserved. A protective sheath is applied to safeguard the incision site. During the operation, nerve monitoring was used in both groups of patients, and the position and function of the recurrent laryngeal nerve could be accurately detected during the operation. (II) No gas injection cavity. The sternocleidomastoid muscle is dissected along its posterior border, extending inferiorly to the point where it attaches to the clavicular head and superiorly to the region where the posterior belly of the digastric muscle converges with the intermediate tendon. Medially and superiorly, the dissection reaches the lateral edge of the superior belly of the omohyoid muscle and the carotid triangle. A retractor is used to elevate the sternocleidomastoid muscle, along with the omohyoid muscle underneath. (III) Expose the thyroid gland. The omohyoid muscle is dissected, and a retractor is placed beneath it to expose the lateral border of the sternothyroid muscle. Depending on the preoperative puncture results, the muscle is either resected or preserved. The ansa cervicalis and its muscular branches are carefully preserved. (IV) Remove the gland. The superior thyroid vessels are dissected and ligated, followed by exposure and preservation of the superior parathyroid gland. The recurrent laryngeal nerve is carefully identified and protected. Subsequently, the middle thyroid vein and inferior thyroid artery and vein are dissected and ligated in sequence, and the thyroid isthmus is divided. (V) Central lymph node dissection. Intraoperative central lymph nodes may be dissected along with the thyroid gland, followed by prelaryngeal, pretracheal, and contralateral central lymph nodes. (VI) Cervical lymph node dissection. Initially, lymph nodes in level III and IIa located medial to the internal jugular vein were excised and sent for intraoperative frozen section analysis as sentinel lymph nodes. If the pathology report indicated positive findings, dissection proceeds to include the lymph nodes in level IIb, located lateral to the internal jugular vein, as well as those in level IV and V. If the results are negative, neck dissection is halted or performed selectively based on preoperative imaging. (VII) Incision suture and drainage. The surgical procedure is shown in Figure 1.

Figure 1 Surgical procedures. (A) Body positioning and incision design; (B) no gas injection cavity; (C) expose thyroid; (D) removal of thyroid gland; (E) central lymph node dissection; (F) lateral neck lymph node dissection.

Statistical analysis

The clinical features, pathological features and perioperative data of the patients were summarized. Quantitative data of normal distribution were expressed as mean ± standard deviation, and t-test was used for comparison between groups. The quantitative data of non-normal distribution were expressed as median [interquartile range (IQR)], and Wilcoxon rank sum test was used for comparison between groups. The statistical data were expressed by component ratio and χ2 test was used for comparison between groups. Logistic regression analysis was used to analyze the influence factors of OLLNM. All statistical analyses were performed using SPSS 26.0 (IBM Corp., Armonk, NY, USA), and a P value <0.05 was statistically significant.


ResultsOther Section

Clinical characteristics and surgical outcomes

In this study, 142 patients with PTC successfully underwent unilateral lobectomy and selective neck lymph node dissection via ETSPIA. Detailed clinical characteristics of the patients are presented in Table 1. The median operative time was 3 h 50 min, with a median intraoperative blood loss of 20 mL and a median postoperative hospital stay of 4 days. The median follow-up period was 17 months. During follow-up, none of the patients reported discomfort such as anterior neck pressure or dysphagia. No transient recurrent laryngeal nerve injury-induced hoarseness was observed. Two patients developed chylous leakage, and four patients experienced postoperative numbness in the extremities, all of whom were discharged after standard treatment. Additionally, five patients reported numbness behind the ears, which resolved within a month. None of the patients received 131I treatment postoperatively.

Table 1

Patient clinical characteristics and perioperative outcomes

Variables No. of patients [%]
Gender
   Male 43 [30]
   Female 99 [70]
Age (years)
   ≤45 89 [63]
   >45 53 [37]
T stage
   T1a 91 [64]
   T1b 37 [26]
   T2 9 [6]
   T3a 0
   T3b 5 [4]
N stage
   N0 60 [42]
   N1a 37 [26]
   N1b 45 [32]
Tumor location
   Upper pole 25 [18]
   Middle 85 [60]
   Lower pole 32 [23]
Tumor number
   Single 108 [76]
   Multiple 34 [24]
Tumor diameter (cm)
   ≤1.0 91 [64]
   >1.0 51 [36]
Capsule invasion
   Yes 72 [51]
   No 70 [49]
Extrathyroidal extension
   Yes 6 [4]
   No 136 [96]
Hashimoto’s thyroiditis
   Yes 35 [25]
   No 107 [75]
Operative time (h)
   ≤4 71 [50]
   >4 71 [50]
Blood loss (mL)
   ≤10 42 [30]
   >10, ≤30 97 [68]
   >30, ≤50 3 [2]
Length of stay (days)
   ≤7 99 [70]
   >7 43 [30]
Postoperative complications
   None 131 [92]
   Chyle leak 2 [1]
   Hoarse voice 0
   Numbness in hands and feet 4 [3]
   Numbness behind the ear 5 [4]

Cervical lymph node metastasis

The cervical lymph node metastasis status of the 142 patients is detailed in Table 2. Preoperative ultrasound indicated that 117 patients had no cervical lymph node metastasis; 14 patients had CLNM, 10 had LLNM, and 1 patient had both CLNM and LLNM. Postoperative pathology confirmed that 64 patients had no lymph node metastasis, 37 had only CLNM, 12 had only LLNM, and 29 had both CLNM and LLNM. Among the 11 patients whose preoperative ultrasound suggested LLNM (characterized by obscured medulla-hilus structure, unclear lymphatic hilum structure, and unevenly enhanced cortical echo), 8 were confirmed to have LLNM postoperatively (overt LLNM), while 3 showed no cervical side metastasis postoperatively. The most common sites for PTC LLNM were the ipsilateral level III and IV regions, followed by levels II and V, with level I being less common. The results of this study indicate that ipsilateral level III OLLNM was most prevalent in PTC patients, followed by levels II and IV. Thirty-three patients presented with OLLNM, wherein preoperative ultrasound did not suggest cervical side metastasis, but postoperative pathology confirmed cervical side metastasis. This group comprised 19 males and 14 females, with a median age of 42 years. Tumor-node-metastasis (TNM) staging included 18 cases of T1a, 7 cases of T1b, 4 cases of T2, and 4 cases of T3b. Tumors were located in the upper pole of the thyroid in 12 cases, the middle part in 15 cases, and the lower pole in 6 cases. There were 26 cases of solitary tumors and 7 cases of multiple foci, with 4 cases exhibiting extrathyroidal extension. Overall, the accuracy rate of preoperative ultrasound for detecting PTC LLNM was 73%.

Table 2

Cervical lymph node metastasis of the patients

Lymph node metastasis No. of patients [%]
Preoperative ultrasound
   No lymph node metastasis 117 [82]
   CLNM 14 [10]
   LLNM 10 [7]
   Both CLNM and LLNM 1 [1]
Postoperative pathology
   No lymph node metastasis 64 [45]
   CLNM 37 [26]
   LLNM 12 [8]
   Both CLNM and LLNM 29 [20]

CLNM, central cervical lymph node metastasis; LLNM, lateral cervical lymph node metastasis.

Factors influencing occult lateral lymph node metastasis

Excluding the 8 cases of overt LLNM, a univariate and multivariate analysis was conducted on the clinical characteristics of 101 patients without LLNM and 33 patients with OLLNM, as shown in Tables 3,4. The univariate analysis indicated that male gender, younger age, higher T stage of the tumor, preoperative ultrasound indicating the tumor located in the upper pole of the thyroid, and extrathyroidal extension were associated with OLLNM (P<0.001, P=0.02, P=0.007, P<0.001, P=0.003 respectively). These factors (gender, age, tumor T stage, tumor location, and extrathyroidal extension) with P<0.05 in the univariate analysis were included in a logistic regression model for multivariate analysis. The results demonstrated that male gender, younger age, preoperative ultrasound indicating the tumor located in the upper pole of the thyroid, and extrathyroidal extension were independent risk factors for OLLNM (P=0.001, P=0.006, P=0.02, P=0.002, respectively).

Table 3

Univariate analysis of influencing factors of OLLNM

Variables Lateral cervical lymph node P value
No OLLNM (n=101) OLLNM (n=33)
Gender <0.001
   Male 22 19
   Female 79 14
Age (years) 43.50±10.24 38.52±9.94 0.02
T stage 0.007
   1a 70 18
   1b 26 7
   2 4 4
   3a 0 0
   3b 1 4
N stage
   0 60 0
   1a 41 0
   1b 0 33
Tumor location <0.001
   Upper pole 8 12
   Middle 69 15
   Lower pole 24 6
Tumor number 0.68
   Single 76 26
   Multiple 25 7
Tumor diameter (cm) 0.12
   ≤1.0 70 18
   >1.0 31 15
Capsule invasion 0.13
   Yes 55 13
   No 46 20
Extrathyroidal extension 0.003
   Yes 1 29
   No 100 4
Number of lymph nodes removed
   Level II positive 0 0.73±0.88
   Level II total 2.41±2.47 5.76±4.17 <0.001
   Level III positive 0 0.97±0.81
   Level III total 3.07±3.09 6.03±2.54 <0.001
   Level IV positive 0 0.21±0.89
   Level IV total 1.22±2.30 3.33±3.27 <0.001
   Level V positive 0 0.03±0.17
   Level V total 0.05±0.41 0.36±0.99 0.01
   Level VI positive 1.22±2.04 2.70±3.11 0.002
   Level VI total 6.36±4.26 6.33±5.02 0.98
Hashimoto’s thyroiditis 0.68
   Yes 25 7
   No 76 26

Data are presented as n or mean ± standard deviation. OLLNM, occult lateral cervical lymph node metastasis.

Table 4

Multivariate logistic regression analysis of influencing factors of OLLNM

Variables β SE Wald Exp (β) P value 95% CI
Gender (male) 2.384 0.557 18.298 10.843 0.001 3.638–32.318
Age −0.079 0.029 7.688 0.924 0.006 0.874–0.977
Tumor location (upper pole) 1.823 0.762 5.717 6.189 0.02 1.389–27.579
Extrathyroidal extension 3.811 1.240 9.452 45.179 0.002 3.980–512.870

OLLNM, occult lateral cervical lymph node metastasis; SE, standard error; Exp (β), odds ratio; CI, confidence interval.


DiscussionOther Section

LLNM is a well-established prognostic factor influencing recurrence and survival in patients with PTC (11). Traditionally, central lymph nodes are considered sentinel nodes for lymphatic drainage in PTC (12), leading both domestic and international guidelines to recommend against prophylactic lateral neck lymph node dissection. Instead, therapeutic dissection is advised when LLNM is confirmed through preoperative assessment or intraoperative frozen section analysis. The dissection typically involves levels II, III, IV, and VB, with the minimal extent including levels II A, III, and IV1. However, previous studies indicate that OLLNM is relatively common in PTC patients. Lim et al. (13) reported an OLLNM incidence as high as 55% in PTC patients undergoing prophylactic lateral neck dissection for ipsilateral CLNM. In our study, postoperative pathology confirmed OLLNM in 25% of patients. Currently, guidelines for unilateral PTC with ipsilateral lateral neck lymph node metastasis, absent other high-risk factors (such as extrathyroidal extension of the primary lesion or lymph nodes, tumor diameter >4 cm, or metastatic lymph nodes ≥3 cm), remain contentious regarding the extent of primary tumor resection. The 2018 guidelines from the Japan Association of Endocrine Surgeons advocate for individualized treatment based on risk stratification, suggesting either unilateral lobectomy or total thyroidectomy depending on prognostic factors and patient conditions. In this study, preoperative imaging did not reveal contralateral thyroid nodules or suspicious contralateral neck lymph nodes. Among the 26 patients with confirmed lateral neck lymph node metastasis, the number of metastatic nodes was relatively low, not exceeding five in any case. According to the 2015 ATA guidelines, such patients may not require postoperative 131I treatment, thus we opted for individualized unilateral lobectomy. Nonetheless, the optimal extent of lateral neck dissection and the necessity for total thyroidectomy in patients with lateral neck lymph node metastasis remain debated. Further research is needed to balance minimizing tumor residuals or recurrence with reducing unnecessary surgical trauma.

Thyroid surgery involving lateral neck lymph node dissection benefits from ETSPIA for several reasons: compared to traditional anterior cervical approaches, ETSPIA offers aesthetic incisions and minimal tissue trauma. Conventional open surgery incisions, such as “L” shaped, “U” shaped, and lower cervical apron-shaped large arc incisions, tend to be long, resulting in prominent postoperative scars that significantly affect the appearance of the neck (14). In contrast, the ETSPIA incision is located within the natural skin folds on the lateral neck, experiencing lower tension and more even fat distribution, promoting better wound healing. Moreover, the incision can be concealed beneath the collar, ensuring postoperative aesthetics (Figure 2). Additionally, open incisions require opening the enveloping fascia, which can cause postoperative anterior cervical pressure, numbness, and discomfort during swallowing. ETSPIA accesses the thyroid surgical area through the deep intermuscular spaces of the strap muscles, avoiding the opening of the enveloping fascia, significantly reducing tissue adhesion in the anterior cervical region, and lowering the risk of transverse cervical nerve injury, thereby significantly alleviating postoperative cervical discomfort. ETSPIA allows for radical dissection of lateral neck lymph nodes compared to other mainstream endoscopic thyroid surgeries. This approach begins with the dissection of lymph nodes in areas III and IIA on the medial side of the internal jugular vein, sending them for intraoperative frozen section analysis as sentinel lymph nodes. If positive, dissection continues to lymph nodes in areas IIB, IV, and V on the lateral side of the internal jugular vein. This method ensures a shorter dissection route with minimal trauma, determining the extent of lateral neck lymph node dissection based on sentinel node results, thus preventing recurrence due to occult metastatic lymph nodes and avoiding unnecessary dissection in all patients, which would increase trauma. Additionally, ETSPIA offers a direct view of the thyroid lobes, accessing the thyroid’s posterior lateral capsule and better protecting the recurrent laryngeal nerve, thyroid suspensory ligament, and superior thyroid artery, reducing the risk of damaging critical structures (15). In this study, no patients experienced transient recurrent laryngeal nerve injury leading to hoarseness postoperatively. In summary, ETSPIA adheres to the new concept of performing endoscopic surgery through natural tissue spaces, characterized by concealed incisions, shorter pathways, minimal tissue trauma, rapid postoperative recovery, and ease of operation for surgeons. It enables radical dissection of lateral neck lymph nodes, representing a truly minimally invasive surgery. This study investigates the value of ETSPIA in treating OLLNM while also analyzing associated factors. PTC manifests differently across gender and age groups, although more prevalent in females (16), PTC tends to be more aggressive in younger males. Girardi et al. (17) validated that, despite a lower incidence of PTC in males, they exhibit a higher propensity for LLNM, consistent with our findings. In our study, younger age emerged as another risk factor for PTC OLLNM. Patron et al. (10) analyzed 173 PTC patients with OLLNM and found that age below 45 years was a risk factor for LLNM. Sugitani et al. (18) hypothesized that this could be due to higher cellular metabolic activity leading to increased lymph node response, though this remains inconclusive. Additionally, our data indicate a significant increase in OLLNM risk when preoperative ultrasound suggests tumor localization in the upper pole of the thyroid gland. In this study, 25 cases had tumors in the upper pole, with 17 exhibiting lateral neck metastasis (68%) and 14 exhibiting central region metastasis (56%). Weng et al. (19) found that PTC in the upper thyroid can lead to skip metastasis to lateral neck lymph nodes, without central lymph node involvement. Tumor cells in the upper pole may be transported via lymphatic vessels to lateral lymph nodes near the superior thyroid artery, facilitating skip metastasis to regions II and III (20,21). Therefore, when preoperative ultrasound indicates tumor presence in the upper pole, lateral neck lymph node dissection is recommended to reduce the likelihood of recurrence and subsequent surgeries due to lymph node metastasis. Moreover, several studies have identified extrathyroidal extension of the tumor as an independent risk factor for LLNM (10,17). In our study, five PTC patients exhibited extrathyroidal extension, with postoperative pathology confirming OLLNM in four cases. The risk factors for OLLNM identified in this study can be ascertained preoperatively and intraoperatively, aiding in the early detection of high-risk PTC patients.

Figure 2 Patient’ s front view of neck. (A) Two months after traditional anterior cervical approach thyroid surgery and lateral cervical lymph node dissection; (B) 2 months after ETSPIA surgery, the incision cannot be seen from the front, and the lateral incision is concealed. These images are published with the patients’ consent. ETSPIA, endoscopic thyroidectomy via sternocleidomastoid muscle posteroinferior approach.

However, ETSPIA has some technical challenges and limitations. For large lesions or thyroid lobes, the limited operating space increases the surgery’s difficulty, requiring careful preoperative evaluation. This approach navigates between the deep surface of the sternocleidomastoid muscle and the carotid sheath, posing a risk of injury to the carotid sheath and hypoglossal nerve loop. This study has limitations, including a small sample size and short follow-up period, and single-center research may introduce errors in the sensitivity and accuracy of preoperative ultrasonographic evaluations. In the future, we plan to expand the case cohort and lengthen the follow-up period to compare ETSPIA with open and other endoscopic thyroidectomy techniques, aiming to comprehensively assess the role of ETSPIA in PTC treatment.


ConclusionsOther Section

Our team has pioneered ETSPIA, utilizing natural tissue spaces to thoroughly clear occult metastatic lateral neck lymph nodes. Additionally, we found that male gender, younger age, tumors located in the upper pole of the thyroid, and extrathyroidal extension are significantly associated with OLLNM, providing valuable insights for the broader application of the ETSPIA. This approach ensures radical thyroid cancer treatment while maximizing postoperative aesthetics and comfort, demonstrating significant clinical application value.


AcknowledgmentsOther Section

Funding: This work was supported by Beijing Hospital Management Center “Ascending the Peak” Talent Training Program (No. DFL20220201).


FootnoteOther Section

Reporting Checklist: The authors have completed the TREND reporting checklist. Available at https://gs.amegroups.com/article/view/10.21037/gs-24-340/rc

Data Sharing Statement: Available at https://gs.amegroups.com/article/view/10.21037/gs-24-340/dss

Peer Review File: Available at https://gs.amegroups.com/article/view/10.21037/gs-24-340/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-24-340/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This retrospective study was approved by the Beijing Tongren Hospital Ethics Committee (No. TREC2023-xjs07) and informed consent was taken from all of the patients.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


ReferencesOther Section

  1. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1856-83. [Crossref] [PubMed]
  2. King JM, Corbitt C, Miller FR. Management of lateral cervical metastases in papillary thyroid cancer: patterns of lymph node distribution. Ear Nose Throat J 2011;90:386-9. [Crossref] [PubMed]
  3. Mulla MG, Knoefel WT, Gilbert J, et al. Lateral cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the lateral compartment. Clin Endocrinol (Oxf) 2012;77:126-31. [Crossref] [PubMed]
  4. Wang Y, Deng C, Shu X, et al. Risk Factors and a Prediction Model of Lateral Lymph Node Metastasis in CN0 Papillary Thyroid Carcinoma Patients With 1-2 Central Lymph Node Metastases. Front Endocrinol (Lausanne) 2021;12:716728. [Crossref] [PubMed]
  5. Patron V, Bedfert C, Le Clech G, et al. Pattern of lateral neck metastases in N0 papillary thyroid carcinoma. BMC Cancer 2011;11:8. [Crossref] [PubMed]
  6. Sapuppo G, Palermo F, Russo M, et al. Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome. J Endocrinol Invest 2017;40:1355-63. [Crossref] [PubMed]
  7. Choi JS, Kim J, Kwak JY, et al. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 2009;193:871-8. [Crossref] [PubMed]
  8. Kim E, Park JS, Son KR, et al. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid 2008;18:411-8. [Crossref] [PubMed]
  9. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133. [Crossref] [PubMed]
  10. Patron V, Hitier M, Bedfert C, et al. Predictive factors for lateral occult lymph node metastasis in papillary thyroid carcinoma. Eur Arch Otorhinolaryngol 2013;270:2095-100. [Crossref] [PubMed]
  11. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2018;68:55-63.
  12. Zhan S, Luo D, Ge W, et al. Clinicopathological predictors of occult lateral neck lymph node metastasis in papillary thyroid cancer: A meta-analysis. Head Neck 2019;41:2441-9. [Crossref] [PubMed]
  13. Lim YS, Lee JC, Lee YS, et al. Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery 2011;150:116-21. [Crossref] [PubMed]
  14. Cai Q, Huang X, Han P, et al. Endoscopy-assisted thyroid surgery via a subclavian approach. Surg Today 2013;43:479-84. [Crossref] [PubMed]
  15. Zhou J, Jing Y, Qi X, et al. A novel minimally invasive endoscopic approach of thyroid surgery-endoscopic thyroidectomy via sternocleidomastoid muscle posteroinferior approach. Gland Surg 2024;13:942-51. [Crossref] [PubMed]
  16. Chen DW, Lang BHH, McLeod DSA, et al. Thyroid cancer. Lancet 2023;401:1531-44. [Crossref] [PubMed]
  17. Girardi FM, Barra MB, Zettler CG. Predictive factors for lymph node metastasis in solitary papillary thyroid carcinomas: a retrospective study. Pathol Oncol Res 2015;21:59-64. [Crossref] [PubMed]
  18. Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 2010;34:1222-31. [Crossref] [PubMed]
  19. Weng HY, Yan T, Qiu WW, et al. The Prognosis of Skip Metastasis in Papillary Thyroid Microcarcinoma Is Better Than That of Continuous Metastasis. J Clin Endocrinol Metab 2022;107:1589-98. [Crossref] [PubMed]
  20. Feng JW, Qin AC, Ye J, et al. Predictive Factors for Lateral Lymph Node Metastasis and Skip Metastasis in Papillary Thyroid Carcinoma. Endocr Pathol 2020;31:67-76. [Crossref] [PubMed]
  21. Sui C, He Q, Du R, et al. Lymph node characteristics of 6279 N1 differentiated thyroid cancer patients. Endocr Connect 2020;9:201-10. [Crossref] [PubMed]
Cite this article as: Jing Y, Zhou J, Qi X, Wu J, Liu H, Huang J, Chen X, Li L, Huang Z, Ding Y, Chen X. Evaluating the efficacy of the endoscopic thyroidectomy via sternocleidomastoid muscle posteroinferior approach in identifying occult lateral cervical lymph node metastasis. Gland Surg 2024;13(11):1986-1995. doi: 10.21037/gs-24-340

Download Citation